Serum Profiling to Distinguish Early- and Late-Stage Ovarian Cancer Patients from Disease-Free Individuals

Sera mass spectrometry (MS) peak differences were analyzed from 35 ovarian cancer patients and 16 disease-free individuals. “Leave one out” cross validation was used to assign “% cancer peaks” in control and ovarian cancer sera samples. Sera MS discriminated stage I/II and stage III/V ovarian cancer patients versus controls with ROC curve area values of 0.82 and 0.92. Test sensitivities for ovarian cancer stage I/II and III/V were 80% and 93% respectively. These results indicate that MS is useful for distinguishing sera from early-stage ovarian cancer patients, and has potential as a test for early detection of this disease.

[1]  M. Lerner,et al.  Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry. , 2011, Lung cancer.

[2]  M. Lerner,et al.  Distinguishing Early-Stage Pancreatic Cancer Patients From Disease-Free Individuals Using Serum Profiling , 2011, Cancer investigation.

[3]  Sandhya Pruthi,et al.  Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. , 2010, Mayo Clinic proceedings.

[4]  A. Keller,et al.  Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening , 2010, British Journal of Cancer.

[5]  W. Holzgreve,et al.  Proteomics and biomarkers for ovarian cancer diagnosis. , 2010, Annals of clinical and laboratory science.

[6]  Alexander G. Gray,et al.  Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines , 2009, BMC Bioinformatics.

[7]  Rasmus Bro,et al.  Feasibility of serodiagnosis of ovarian cancer by mass spectrometry. , 2009, Analytical chemistry.

[8]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[9]  Feng Su,et al.  The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? , 2008, American journal of obstetrics and gynecology.

[10]  M. Lerner,et al.  Biomarker Identification in Human Pancreatic Cancer Sera , 2008, Pancreas.

[11]  M. Suchard,et al.  Validation of Candidate Serum Ovarian Cancer Biomarkers for Early Detection , 2007, Biomarker insights.

[12]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[13]  Wei Zhang,et al.  Application of serum SELDI proteomic patterns in diagnosis of lung cancer , 2005, BMC Cancer.

[14]  Weijian Guo,et al.  Prediction of Pancreatic Cancer by Serum Biomarkers Using Surface-Enhanced Laser Desorption/Ionization-Based Decision Tree Classification , 2005, Oncology.

[15]  G. Hortin.  Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? , 2005, Clinical chemistry.

[16]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[17]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[18]  Min Zhan,et al.  A data review and re-assessment of ovarian cancer serum proteomic profiling , 2003, BMC Bioinformatics.

[19]  M. Lerner,et al.  DNA Ploidy and Markovian Analysis of Neoplastic Progression in Experimental Pancreatic Cancer , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[21]  S M Hanash,et al.  Proteomic Approaches within the NCI Early Detection Research Network for the Discovery and Identification of Cancer Biomarkers , 2001, Annals of the New York Academy of Sciences.

[22]  G I Murray,et al.  Proteomics: a new approach to the study of disease , 2000, The Journal of pathology.

[23]  M. Schrader,et al.  Composition of the peptide fraction in human blood plasma: database of circulating human peptides. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[24]  D. Altman,et al.  Statistics Notes: Diagnostic tests 2: predictive values , 1994, BMJ.

[25]  D. Altman,et al.  Statistics Notes: Diagnostic tests 1: sensitivity and specificity , 1994 .

[26]  I sabel Mortara,et al.  International Union against Cancer , 1938, Nature.